This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Symbicort SMART Satisfaction From Patient Perspective 2009

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: July 24, 2009
Last updated: March 17, 2010
Last verified: March 2010
To characterize the level of asthma control and patient satisfaction amongst diagnosed asthma sufferers who are currently receiving Symbicort Maintenance and Reliever Therapy (SMART) in Malaysia.


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Symbicort SMART Satisfaction From Patient Perspective 2009

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Score level of Satisfaction in Asthma Treatment Questionnaire (SATQ) [ Time Frame: After 3 months on SMART - once ]
  • Score level of Asthma Control Test (ACT) [ Time Frame: After 3 months on SMART - once ]

Enrollment: 205
Study Start Date: August 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  • Have been prescribed Symbicort SMART (1 or 2 inhalation twice daily) by their Dr's for the past 3 months
  • Informed consent

Exclusion Criteria:

  • Symbicort SMART treatment < 3 months
  • Patients requiring short courses of oral steroids more than twice in a month
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00946452

Research Site
Petaling Jaya, Selangor, Malaysia
Sponsors and Collaborators
Principal Investigator: Liam Chong Kin, Professor UMMC
  More Information

Responsible Party: MC MD, AstraZeneca Pharmaceuticals Identifier: NCT00946452     History of Changes
Other Study ID Numbers: NIS-RMY-SYM-2009/1
Study First Received: July 24, 2009
Last Updated: March 17, 2010

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents processed this record on August 18, 2017